Bass, Berry & Sims attorney Jeff Davis was recently featured in a Bloomberg Law article examining efforts by healthcare providers, pharmaceutical manufacturers, and lawmakers to reshape the future of the federal 340B Drug Pricing Program.
The article explores competing legislative proposals and ongoing litigation surrounding the use of rebate models for 340B drug discounts. While manufacturers have advocated for systems that replace upfront discounts with rebates, hospitals and other covered entities have raised concerns about the financial and administrative burdens such an approach could create.
The article highlights how policymakers, providers, and manufacturers are pursuing parallel paths to influence the program’s future. Several bipartisan bills introduced this year would take significantly different approaches to rebate models and program oversight, while legal challenges continue to shape how regulators and stakeholders implement potential changes.
Discussing the current legislative landscape, Jeff noted that lawmakers are considering a range of proposals aimed at broader reform of the program. “A number of these bills are attempting to be big, major, comprehensive 340B reform,” he said.
The full article, “Drugmakers, Providers Push Congress on Drug Discount Rebates,” was published in Bloomberg Law on September 14 and is available online.